Category: Reduced
-
Bitcoin Leverage Reduced On Major Exchanges – Calm Before The Storm?
•
Bitcoin is now in a decisive and unconfirmed stage, as it was combined without a sign of 100 thousand dollars and above the level of demand for 95 thousand dollars, as the feelings in the market are still divided. The short -term price procedure does not show any clear orientation,…
-
Bitcoin Price Takes a Breather: Gains Reduced Amid Volatility
•
Bitcoin price failed to stay above the $100,000 area. BTC is correcting gains and may have difficulty staying above the $96,000 support area. Bitcoin started a new decline from the $102,500 resistance area. The price is trading below $100,000 and the 100 hourly simple moving average. There was a breakout…
-
Ethereum Could Reclaim $2,700 As Key Data Signals Reduced Selling Pressure
•
This article is also available in Spanish. Ethereum (ETH) is currently trading roughly 11% below its local highs of around $2,730. Investors are optimistic about the potential price rise in the coming days, driven by encouraging on-chain data. Key metrics from Glassnode indicate that ETH inflows to exchanges are declining,…
-
Hotter U.S. Core Inflation Reduced The Odds Of A 50bps Fed Rate Cut
•
The US Bureau of Labor Statistics data showed that the headline inflation rate in the United States was 0.2% on a monthly basis in August, the same as July and analysts’ estimates. Annual inflation slowed sharply from 2.9% to 2.5%, slower than market expectations of 2.7%. In fact, 2.5% is…
-
Hotter U.S. Core Inflation Reduced The Odds Of A 50bps Fed Rate Cut
•
The US Bureau of Labor Statistics data showed that the headline inflation rate in the United States was 0.2% on a monthly basis in August, the same as July and analysts’ estimates. Annual inflation slowed sharply from 2.9% to 2.5%, slower than market expectations of 2.7%. In fact, 2.5% is…
-
Cooler Core Inflation In Australia Reduced RBA Rate Hike Odds
•
Australian Bureau of Statistics data showed that inflation in Australia maintained its quarterly growth of 1.0% in the second quarter of 2024, which was driven by price increases in food, clothing, alcohol and tobacco products. On an annual basis, the pace of price increases accelerated from 3.6% to 3.8% in…
-
CALQUENCE ® (acalabrutinib) plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial
•
First and only BTK inhibitor to demonstrate favorable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting WILMINGTON, Del.–(BUSINESS WIRE)–Positive results from the ECHO Phase III trial showed AstraZeneca (NASDAQ:)’s CALQUENCE ® (acalabrutinib) in combination with bendamustine and rituximab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival…